Sorafenib 200 MG Oral Tablet [Nexavar] — RxCUI 615979
RxNorm drug concept · Semantic branded drug
RxCUI 615979
Semantic branded drug · SBD
● Current RxNorm concept 2 FDA products
2 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI615979
Official nameSorafenib 200 MG Oral Tablet [Nexavar]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asNexavar 200 MG Oral Tablet
FDA products mapped2
Package NDCs mapped2
Reported Medicaid activity (SDUD)123 prescriptions · 2 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Sorafenib: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Sorafenib — sold as the brand Nexavar or as a generic — is approved for three specific cancers: liver cancer that can't be surgically removed (hepatocellular carcinoma), advanced k...
- What cancers does sorafenib actually treat?
- Yes — it really does. You should take sorafenib on an empty stomach, at least 1 hour before eating or 2 hours after a meal. A high-fat meal can reduce how much of the medicine your...
- Does it matter if I take sorafenib with food?
🕸️ Concept Web — How Sorafenib 200 MG Oral Tablet [Nexavar] Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Sorafenib 200 MG Oral Tablet [Nexavar]
RxCUI 615979 Semantic branded drug · SBD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Sorafenib
495881IN
-
Sorafenib
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Nexavar
619985BN
-
Nexavar
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Sorafenib Oral Tablet
597746SCDF -
Sorafenib Oral Product
1159691SCDG -
Sorafenib Pill
1159692SCDG -
Sorafenib Oral Tablet [Nexavar]
615978SBDF -
Nexavar Oral Product
1182862SBDG -
Nexavar Pill
1182863SBDG -
Oral Tablet
317541DF -
Oral Product
1151131DFG - +1 more in this family
-
Sorafenib Oral Tablet
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Sorafenib 200 MG Oral Tablet
597747SCD -
Sorafenib 200 MG
597745SCDC -
Sorafenib 200 MG [Nexavar]
615977SBDC
-
Sorafenib 200 MG Oral Tablet
Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Sorafenib 200 MG Oral Tablet
SCD · 597747 -
Sorafenib 200 MG
SCDC · 597745 -
Sorafenib Oral Tablet
SCDF · 597746 -
Sorafenib Oral Product
SCDG · 1159691 -
Sorafenib Pill
SCDG · 1159692
Brand-Name Concepts
-
Sorafenib 200 MG [Nexavar]
SBDC · 615977 -
Sorafenib Oral Tablet [Nexavar]
SBDF · 615978 -
Nexavar Oral Product
SBDG · 1182862 -
Nexavar Pill
SBDG · 1182863 -
Nexavar
BN · 619985
📦 FDA Products & Package NDCs
2 products · 2 package NDCs
2 package NDCs map to RxCUI 615979 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 50419-0488-58 | 120 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (50419-488-58) | Nexavar | Bayer HealthCare Pharmaceuticals Inc. | 2005-12-20 |
| 50419-0489-01 | 120 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (50419-489-01) | Nexavar | Bayer HealthCare Pharmaceuticals Inc. | 2023-10-02 |
Observed labelers:
Bayer HealthCare Pharmaceuticals Inc. (2)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.